Eli Lilly (LLY) Stock: Strong Earnings Beat Sends Shares Soaring on Weight-Loss Drug Growth

TLDR Eli Lilly reported Q4 adjusted earnings of $7.54 per share, beating analyst expectations of $6.91 Quarterly revenue reached $19.3 billion, exceeding the $17.9 billion estimate and up 43% year-over-year Mounjaro revenue more than doubled to $7.4 billion while Zepbound revenue jumped 123% to $4.3 billion Full-year 2026 guidance projects revenue between $80-83 billion, above [...]

The post Eli Lilly (LLY) Stock: Strong Earnings Beat Sends Shares Soaring on Weight-Loss Drug Growth appeared first on Blockonomi.